
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Orthocell Limited is a biotechnology business based in Australia. Orthocell shares (OCC) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Orthocell has a trailing 12-month revenue of around $719,523.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.18 - $0.585 |
---|---|
50-day moving average | $0.5325 |
200-day moving average | $0.4376 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.049 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | $719,523 |
---|---|
Gross profit TTM | $214,149 |
Return on assets TTM | -31.18% |
Return on equity TTM | -38.9% |
Profit margin | 0% |
Book value | 0.113 |
Market capitalisation | $99.1 million |
TTM: trailing 12 months
We're not expecting Orthocell to pay a dividend over the next 12 months.
Over the last 12 months, Orthocell 's shares have ranged in value from as little as $0.18 up to $0.585. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Orthocell 's is 0.309. This would suggest that Orthocell 's shares are less volatile than average (for this exchange).
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.
You can now invest as little as 1 cent into Australian, NZ and US shares. Here's why that's a game changer.
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
Everything we know about the Deliveroo IPO, plus information on how to buy in.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.